keyword
https://read.qxmd.com/read/38465068/epidermolysis-bullosa-practical-clinical-tips-from-the-field
#21
REVIEW
Aaron Tabor, Jo Ann K LeQuang, Joseph Pergolizzi
Epidermolysis bullosa (EB) is a rare genetic condition characterized by fragile skin caused by impaired adhesion between the dermis and epidermis. EB is present at or near birth. There is no cure and treatments are supportive. Children with EB are at elevated risk of squamous cell cancer. Under ideal circumstances, EB patients benefit from interdisciplinary care teams who can offer state-of-the-art treatments. In reality and particularly in less-developed nations, care can be limited. In all cases, families dealing with a member with EB face great challenges in caregiving, much of which is managed at home, and incur great financial expenses for dressings, equipment, transportation, and out-of-pocket expenses...
February 2024: Curēus
https://read.qxmd.com/read/38463656/pregnancy-associated-blistering-in-a-patient-with-junctional-epidermolysis-bullosa
#22
Lily Hertel, Mollie Hutton, Paul Bogner, Raminder Grover, Drew Kuraitis
No abstract text is available yet for this article.
April 2024: JAAD Case Reports
https://read.qxmd.com/read/38462666/antiviral-drugs-prolong-survival-in-murine-recessive-dystrophic-epidermolysis-bullosa
#23
JOURNAL ARTICLE
Grace Tartaglia, Ignacia Fuentes, Neil Patel, Abigail Varughese, Lauren E Israel, Pyung Hun Park, Michael H Alexander, Shiv Poojan, Qingqing Cao, Brenda Solomon, Zachary M Padron, Jonathan A Dyer, Jemima E Mellerio, John A McGrath, Francis Palisson, Julio Salas-Alanis, Lin Han, Andrew P South
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin disease characterized by defects in type VII collagen leading to a range of fibrotic pathologies resulting from skin fragility, aberrant wound healing, and altered dermal fibroblast physiology. Using a novel in vitro model of fibrosis based on endogenously produced extracellular matrix, we screened an FDA-approved compound library and identified antivirals as a class of drug not previously associated with anti-fibrotic action. Preclinical validation of our lead hit, daclatasvir, in a mouse model of RDEB demonstrated significant improvement in fibrosis as well as overall quality of life with increased survival, weight gain and activity, and a decrease in pruritus-induced hair loss...
March 10, 2024: EMBO Molecular Medicine
https://read.qxmd.com/read/38462136/cost-of-hospitalization-for-care-of-children-with-epidermolysis-bullosa-in-the-us
#24
JOURNAL ARTICLE
Amar D Desai, Amit Singal, Sara Behbahani, Yssra Soliman, Elena B Hawryluk
No abstract text is available yet for this article.
March 8, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38459694/on-and-off-target-effects-of-paired-crispr-cas-nickase-in-primary-human-cells
#25
JOURNAL ARTICLE
Julia Klermund, Manuel Rhiel, Thomas Kocher, Kay Ole Chmielewski, Johannes Bischof, Geoffroy Andrieux, Melina El Gaz, Stefan Hainzl, Melanie Boerries, Tatjana I Cornu, Ulrich Koller, Toni Cathomen
Undesired on- and off-target effects of CRISPR-Cas nucleases remain a challenge in genome editing. While the use of Cas9 nickases has been shown to minimize off-target mutagenesis, their use in therapeutic genome editing has been hampered by a lack of efficacy. To overcome this limitation, we and others have developed double nickase-based strategies to generate staggered DNA double-strand breaks to mediate gene disruption or gene correction with high efficiency. However, the impact of paired single-strand nicks on genome integrity has remained largely unexplored...
March 7, 2024: Molecular Therapy
https://read.qxmd.com/read/38459626/stop-codon-readthrough-as-a-treatment-option-for-epidermolysis-bullosa-where-we-are-and-where-we-are-going
#26
REVIEW
Johanna Zandanell, Michael Wießner, Johann W Bauer, Roland N Wagner
In the context of rare genetic diseases caused by nonsense mutations, the concept of induced stop codon readthrough (SCR) represents an attractive avenue in the ongoing search for improved treatment options. Epidermolysis bullosa (EB)-exemplary for this group of diseases-describes a diverse group of rare, blistering genodermatoses. Characterized by extreme skin fragility upon minor mechanical trauma, the most severe forms often result from nonsense mutations that lead to premature translation termination and loss of function of essential proteins at the dermo-epidermal junction...
March 2024: Experimental Dermatology
https://read.qxmd.com/read/38459407/gene-edited-cells-novel-allogeneic-gene-cell-therapy-for-epidermolysis-bullosa
#27
REVIEW
Fatemeh Gila, Vahab Alamdari-Palangi, Maedeh Rafiee, Arezoo Jokar, Sajad Ehtiaty, Aria Dianatinasab, Seyyed Hossein Khatami, Mortaza Taheri-Anganeh, Ahmad Movahedpour, Jafar Fallahi
Epidermolysis bullosa (EB) is a group of rare genetic skin fragility disorders, which are hereditary. These disorders are associated with mutations in at least 16 genes that encode components of the epidermal adhesion complex. Currently, there are no effective treatments for this disorder. All current treatment approaches focus on topical treatments to prevent complications and infections. In recent years, significant progress has been achieved in the treatment of the severe genetic skin blistering condition known as EB through preclinical and clinical advancements...
March 9, 2024: Journal of Applied Genetics
https://read.qxmd.com/read/38451422/the-need-of-differential-diagnosis-between-vulvar-lichen-sclerosus-and-autoimmune-dermatoses-in-adolescent-girls
#28
JOURNAL ARTICLE
Agnieszka Dulska, Jakub Bodziony, Marta Janik, Agnieszka Drosdzol-Cop
INTRODUCTION: Vulvar lichen sclerosus (VLS) is a chronic inflammatory condition affecting the anogenital region, which can manifest in prepubertal or adolescent patients. The prevailing theories point to autoimmune and genetic factors. The primary symptoms of VLS typically include vulvar itching, discomfort, dysuria, and constipation. Physical examination often reveals a characteristic figure 8 pattern, involving the labia minora, clitoral hood, and perianal region. However, these symptoms and the age of onset are nonspecific and require differentiation from autoimmune dermatoses such as bullous diseases, pemphigus diseases, epidermolysis bullosa acquisita, and dermatitis herpetiformis...
March 7, 2024: Dermatology and Therapy
https://read.qxmd.com/read/38430362/advances-in-treatments-for-epidermolysis-bullosa-eb-emphasis-on-stem-cell-based-therapy
#29
REVIEW
Ramin Raoufinia, Hamid Reza Rahimi, Neda Keyhanvar, Meysam Moghbeli, Nima Abdyazdani, Mehdi Rostami, Karim Naghipoor, Fatemeh Forouzanfar, Sara Foroudi, Ehsan Saburi
Epidermolysis bullosa (EB) is a rare genetic dermatosis characterized by skin fragility and blister formation. With a wide phenotypic spectrum and potential extracutaneous manifestations, EB poses significant morbidity and mortality risks. Currently classified into four main subtypes based on the level of skin cleavage, EB is caused by genetic mutations affecting proteins crucial for maintaining skin integrity. The management of EB primarily focuses on preventing complications and treating symptoms through wound care, pain management, and other supportive measures...
March 2, 2024: Stem cell reviews and reports
https://read.qxmd.com/read/38429928/lentiviral-expression-of-wildtype-lama3a-restores-cell-adhesion-in-airway-basal-cells-from-children-with-epidermolysis-bullosa
#30
JOURNAL ARTICLE
Chun Hang Lau, Maral J Rouhani, Elizabeth F Maughan, Jessica C Orr, Krishna K Kolluri, David R Pearce, Elizabeth Haughey, Liam Sutton, Sam Flatau, Pablo Lopez Balboa, Maria Laura Bageta, Christopher O'Callaghan, Claire M Smith, Sam M Janes, Richard Hewitt, Gabriela Petrof, Anna E Martinez, John A McGrath, Colin R Butler, Robert E Hynds
The hallmark of epidermolysis bullosa (EB) is fragile attachment of epithelia due to genetic variants in cell adhesion genes. We describe 16 EB patients treated in the Ear, Nose and Throat department of a tertiary pediatric hospital linked to the United Kingdom's National EB unit between 1992 and 2023. Patients suffered a high degree of morbidity and mortality from laryngotracheal stenosis. Variants in laminin subunit alpha-3 (LAMA3) were found in 10/15 patients where genotype was available. LAMA3 encodes a subunit of the laminin-332 heterotrimeric extracellular matrix protein complex and is expressed by airway epithelial basal stem cells...
February 29, 2024: Molecular Therapy
https://read.qxmd.com/read/38429888/elevated-expression-of-interleukin-6-il-6-and-serum-amyloid-a-saa-in-the-skin-and-the-serum-of-recessive-dystrophic-epidermolysis-bullosa-skin-as-a-possible-source-of-il-6-through-toll-like-receptor-ligands-and-saa
#31
JOURNAL ARTICLE
Yoshio Kawakami, Ai Kajita, Ken-Ichi Hasui, Yoshihiro Matsuda, Keiji Iwatsuki, Shin Morizane
The effect of persistent skin inflammation on extracutaneous organs and blood is not well studied. Patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of the inherited blistering skin disorder, have widespread and persistent skin ulcers, and they develop various complications including anaemia, hyperglobulinaemia, hypoalbuminaemia and secondary amyloidosis. These complications are associated with the bioactivities of IL-6, and the development of secondary amyloidosis requires the persistent elevation of serum amyloid A (SAA) level...
March 2024: Experimental Dermatology
https://read.qxmd.com/read/38415502/self-improving-dystrophic-epidermolysis-bullosa-with-a-novel-heterozygous-missense-variant-in-the-col7a1-gene-in-a-taiwanese-family
#32
JOURNAL ARTICLE
Yi-Chia Tsai, Wei-Ting Tu, Chun-Lin Su, Yu-Wen Cheng, Pei-Ling Chi, Chao-Kai Hsu, Yang-Yi Chen
Self-improving dystrophic epidermolysis bullosa (DEB) is a genodermatosis that is inherited autosomal dominantly or recessively, and its clinical symptoms may improve or subside spontaneously. Herein, we report a case of self-improving DEB with COL7A1 p.Gly2025Asp variant. The diagnosis was made through histopathological, electron microscopic examination, and genetic testing. The same variant is also noted on his father, who presents with dystrophic toenails without any blisters. This study highlights that idiopathic nail dystrophy could be linked to congenital or hereditary disease...
February 28, 2024: Wound Repair and Regeneration
https://read.qxmd.com/read/38414793/identification-of-novel-krt5-gene-variants-in-two-chinese-patients-with-sporadic-form-of-epidermolysis-bullosa-simplex-a-case-report
#33
Linli Liu, Qinglian Lu, Hui Luo, Chunshui Yu
Epidermolysis bullosa simplex (EBS), a rare genetic disorder characterized by fragile skin that is prone to blistering and tearing, is primarily caused by mutations in genes encoding keratin proteins, such as KRT5 and KRT14 . This study aimed to identify the pathogenic gene variants responsible for the sporadic form of EBS in two Chinese patients. Blood samples were collected from patients and their parents, and next-generation sequencing (NGS) was performed for variant screening. Two novel gene variants were identified within the KRT5 gene: c...
April 2024: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/38403552/hereditary-epidermolysis-bullosa-clinical-epidemiological-profile-of-278-patients-at-a-tertiary-hospital-in-s%C3%A3-o-paulo-brazil
#34
JOURNAL ARTICLE
I T Chan, Vanessa Rolim Bessa, Isadora Zago Miotto, Luciana Paula Samorano, Maria Cecília Rivitti-Machado, Zilda Najjar Prado de Oliveira
BACKGROUND: Epidermolysis bullosa (EB) is a group of rare hereditary diseases, characterized by fragility of the skin and mucous membranes. Epidemiological data on EB in Brazil are scarce. OBJECTIVES: To describe epidemiological aspects of patients with EB diagnosed in the Dermatology Department of a tertiary hospital, from 2000 to 2022. METHODS: An observational and retrospective study was conducted through the analysis of medical records...
February 24, 2024: Anais Brasileiros de Dermatologia
https://read.qxmd.com/read/38401849/cyclization-enhanced-poly-%C3%AE-amino-ester-s-vectors-for-efficient-crispr-gene-editing-therapy
#35
JOURNAL ARTICLE
Xianqing Wang, Yinghao Li, A Sigen, Jing Lyu, Xi Wang, Zhonglei He, Irene Lara-Sáez, Ming Li, Wenxin Wang
Among non-viral gene delivery vectors, poly(β-amino ester)s (PAEs) are one of the most versatile candidates because of their wide monomer availability, high polymer flexibility, and superior gene transfection performance both in vitro and in vivo. Over two decades, PAEs have evolved from linear to highly branched structures, significantly enhancing gene delivery efficacy. Building on the proven efficient sets of monomers in highly branched PAEs (HPAEs), this work introduced a new class of cyclic PAEs (CPAEs) constructed via an A2  + B4  + C2 cyclization synthesis strategy and identified their markedly improved gene transfection capabilities in gene delivery applications...
February 22, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38399557/rituximab-in-the-management-of-autoimmune-bullous-diseases-a-treatment-resistant-case-series-from-a-single-central-european-referral-center
#36
JOURNAL ARTICLE
Maciej Marek Spałek, Magdalena Jałowska, Monika Bowszyc-Dmochowska, Marian Dmochowski
Background and Objectives : Rituximab (RTX) has been the predominant treatment for autoimmune bullous diseases (AIBDs). The objective of this research was to assess the advantages and safety characteristics of RTX treatment in individuals with AIBD. This assessment focused on clinical remission and a reduction in glucocorticosteroid usage, its effect on the titers of autoantibodies targeting desmoglein-1 (DSG-1) and desmoglein-3 (DSG-3), and adverse occurrences during a 12-month follow-up period in a dermatology department within a Central European university context...
February 4, 2024: Medicina
https://read.qxmd.com/read/38396920/emerging-gene-therapeutics-for-epidermolysis-bullosa-under-development
#37
REVIEW
Johannes Bischof, Markus Hierl, Ulrich Koller
The monogenetic disease epidermolysis bullosa (EB) is characterised by the formation of extended blisters and lesions on the patient's skin upon minimal mechanical stress. Causal for this severe condition are genetic mutations in genes, leading to the functional impairment, reduction, or absence of the encoded protein within the skin's basement membrane zone connecting the epidermis to the underlying dermis. The major burden of affected families justifies the development of long-lasting and curative therapies operating at the genomic level...
February 13, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38389191/patients-suffering-from-dystrophic-epidermolysis-bullosa-are-prone-to-developing-autoantibodies-against-skin-proteins-a-longitudinal-confirmational-study
#38
JOURNAL ARTICLE
J Bremer, H H Pas, G F H Diercks, H J Meijer, S M van der Molen, A M Nijenhuis, L L van Nijen-Vos, P Morandé, M J Yubero, F Palisson, I Fuentes, A M G Pasmooij
Epidermolysis bullosa (EB) is a heritable skin blistering disease caused by variants in genes coding for proteins that secure cell-cell adhesion and attachment of the epidermis to the dermis. Interestingly, several proteins involved in inherited EB are also associated with autoimmune blistering diseases (AIBD). In this study, we present a long-term follow-up of 15 patients suffering from recessive dystrophic or junctional EB. From these patients, 62 sera were analysed for the presence of autoantibodies associated with AIBD...
February 2024: Experimental Dermatology
https://read.qxmd.com/read/38387013/epidemiological-assessment-of-a-pediatric-palliative-care-clinic-at-a-brazilian-quaternary-hospital-20-years-of-experience
#39
JOURNAL ARTICLE
Gustavo Marquezani Spolador, Fernanda Bastos, Rita Tiziana Verardo Polastrini, Ivete Zoboli, Ana Cristina Henrique, Joaquim Pinheiro Vieira Filho, Mariana Ribeiro Marcondes da Silveira, Elaine Freitas, Andréa Gislene do Nascimento, Silvia Maria de Macedo Barbosa
Background: The pediatric palliative care (PPC) sets up an interdisciplinary approach of chronic complex diseases throughout birth to adolescence. It encompasses countless contrasts in development and diagnosis scopes, which make this area a challenge to nonpediatric practitioners. Objective: We sought to assess the most prevalent diseases in follow-up of the PPC team. Methods: We analyzed the medical records of PPC clinic during the years 2001 and 2021 and the diagnosis of outpatients. We established a parallel with the world scientific literature concerning the epidemiology of PPC...
February 22, 2024: Journal of Palliative Medicine
https://read.qxmd.com/read/38378631/totally-endoscopic-concomitant-aortic-and-mitral-valve-surgery-in-junctional-epidermolysis-bullosa-a-case-report
#40
JOURNAL ARTICLE
Kazufumi Yoshida, Soshi Yoshida, Yoshimasa Hori, Hideki Tsubota, Ryosuke Mochizuki, Tohru Nagano, Tadaaki Koyama
BACKGROUND: Junctional epidermolysis bullosa is a rare skin and mucosal disorder characterized by blister formation in response to minor trauma and extracutaneous manifestations. There have been no reports of cardiac surgery and prognostication in patients with epidermolysis bullosa due to skin and mucosal fragility. CASE PRESENTATION: A 55-year-old man presented with congenital junctional epidermolysis bullosa, hypertension, and vasospastic angina. He complained of dyspnea on exertion, and transthoracic echocardiography revealed severe aortic valve regurgitation, moderate aortic valve stenosis (tricuspid valve), and severe mitral valve regurgitation...
February 20, 2024: Journal of Cardiothoracic Surgery
keyword
keyword
36077
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.